dc.creator | Zachos, I. | en |
dc.creator | Konstantinopoulos, P. A. | en |
dc.creator | Vandoros, G. P. | en |
dc.creator | Karamouzis, M. V. | en |
dc.creator | Papatsoris, A. G. | en |
dc.creator | Podimatas, T. | en |
dc.creator | Papachristodoulou, A. | en |
dc.creator | Chrisofos, M. | en |
dc.creator | Deliveliotis, C. | en |
dc.creator | Papavassiliou, A. G. | en |
dc.date.accessioned | 2015-11-23T10:54:34Z | |
dc.date.available | 2015-11-23T10:54:34Z | |
dc.date.issued | 2009 | |
dc.identifier | 10.1007/s00432-009-0557-9 | |
dc.identifier.issn | 0171-5216 | |
dc.identifier.uri | http://hdl.handle.net/11615/34771 | |
dc.description.abstract | We conducted a prospective study to determine whether expression of telomerase reverse transcriptase (hTERT) is associated with recurrence-free-survival (RFS) or development of invasive disease in patients with high risk superficial bladder cancer (SBC) that received adjuvant BCG immunotherapy. Thirty patients with high-grade T1 tumors were evaluated. Pre-BCG TURBT and post-BCG specimens were analyzed for hTERT nucleolar expression by immunohistochemistry. Post-BCG hTERT expression was statistically significantly lower than pre-BCG hTERT expression. Pre-BCG hTERT nucleolar staining in more than 75% of cells was associated with worse RFS (9 months vs. not yet reached, P = 0.05), while post-BCG hTERT nucleolar staining in more than 50% of the cells was associated with worse RFS (6 months vs. not yet reached, P = 0.001) and development of invasive disease. In multivariate analysis, post-BCG hTERT expression was independently associated with RFS and development of invasive disease. Immunohistochemical evaluation of hTERT may help define a subset of high risk SBC patients that will eventually fail BCG and may therefore benefit from early salvage cystectomy. | en |
dc.source | Journal of Cancer Research and Clinical Oncology | en |
dc.source.uri | <Go to ISI>://WOS:000268512800004 | |
dc.subject | Superficial bladder cancer | en |
dc.subject | Telomerase reverse transcriptase | en |
dc.subject | BCG | en |
dc.subject | Recurrence | en |
dc.subject | Multivariate analysis | en |
dc.subject | BACILLUS-CALMETTE-GUERIN | en |
dc.subject | DIFFERENTIAL EXPRESSION | en |
dc.subject | NUCLEOLAR | en |
dc.subject | LOCALIZATION | en |
dc.subject | COLORECTAL METASTASES | en |
dc.subject | CATALYTIC SUBUNIT | en |
dc.subject | TUMOR | en |
dc.subject | PROGRESSION | en |
dc.subject | IN-VITRO | en |
dc.subject | HTERT | en |
dc.subject | SURVIVAL | en |
dc.subject | CARCINOMA | en |
dc.subject | Oncology | en |
dc.title | Predictive value of telomerase reverse transcriptase expression in patients with high risk superficial bladder cancer treated with adjuvant BCG immunotherapy | en |
dc.type | journalArticle | en |